Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset

Simply Wall St.03-03

AdvertisementEarnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616346369?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-03 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616346369","market":"us","top_or_hot":-1,"title":"Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEarnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 18:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEarnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","article_id":"2616346369","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/assessing-neuren-pharmaceuticals-asxneu-valuation-after-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616346369","pubTimestamp":1772533526,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earnings trigger and why Neuren is on radar\nNeuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year.\nSee our latest analysis for Neuren Pharmaceuticals.\nThe share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","NEU":"NewMarket"},"translate_title":"评估Neuren Pharmaceuticals(ASX：NEU)最新年度收益重置后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1.5,"NEU":1.5},"content_text":"AdvertisementEarnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year 2025 results, reporting revenue of A$84.84 million and net income of A$30.44 million, both lower than the prior year. See our latest analysis for Neuren Pharmaceuticals. The share price reaction has been sharp, with a 1 day share price return of an 8.79% decline and a 30 day share price return of a 24.75% decline. The 1 year total shareholder return of 1.87% and 3 year total shareholder return of 64.18% suggest earlier optimism has faded recently as the latest earnings reset expectations and risk perceptions around Neuren’s growth story. If you are weighing how this kind of earnings shock compares with other opportunities in healthcare, it may be worth scanning 10 healthcare AI stocks as a starting point for fresh ideas. With earnings now sharply lower and the share price off its highs, the key question is whether Neuren’s current valuation reflects a temporary reset, or whether the market is already pricing in all the future growth potential. Most Popular Narrative: 46.4% Undervalued Neuren’s most followed valuation narrative puts fair value at A$23.45 per share, compared with the last close of A$12.56. This frames the recent share price pullback very differently to the headline earnings shock.  The analysts have a consensus price target of A$24.512 for Neuren Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$30.5, and the most bearish reporting a price target of just A$21.2.  Read the complete narrative. Read the complete narrative. Curious how a high margin profile, shrinking share count and a richer future earnings multiple combine into that fair value line? The narrative leans heavily on earnings power several years out and assumes a very specific trade off between slower revenue in A$ terms and higher profitability. The interesting part is how those inputs get discounted back at just under 7% to bridge today’s price with that valuation. Result: Fair Value of A$23.45 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on key uncertainties, including Neuren’s reliance on Acadia for DAYBUE royalties and future FDA decisions that could shift timelines or earnings expectations. Find out about the key risks to this Neuren Pharmaceuticals narrative. Another View: Earnings Multiple Paints a Tougher Picture The fair value estimate of A$23.45 suggests upside, but the earnings multiple tells a very different story. Neuren trades on a P/E of 52.3x, compared with 22.2x for the global pharmaceuticals group, a peer average of 18.5x and a fair ratio of 33.2x. This gap means you are paying a much richer price for each A$ of earnings than both peers and the fair ratio imply, which could leave less room for error if forecasts change. So which lens do you rely on more when the signals conflict this clearly? See what the numbers say about this price — find out in our valuation breakdown. ASX:NEU P/E Ratio as at Mar 2026Next Steps If this mix of signals feels conflicted, do not wait for a consensus to form before you look closer. Check the 2 key rewards and weigh those positives for yourself. Looking for more investment ideas? If Neuren has sharpened your focus, do not stop here. Put that momentum to work by lining up a few more potential candidates now, while they are front of mind.  Target value first and see which companies screen as 7 high quality undervalued stocks based on quality fundamentals and pricing. Prioritise resilience by reviewing companies in our 7 resilient stocks with low risk scores that score well on balance sheet strength and risk metrics. Hunt for underfollowed names using the screener containing 12 high quality undiscovered gems, where solid fundamentals meet lower market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neuren Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616346369","isCrawlerRequest":true}